Literature DB >> 16399419

Management of stage T1 tumors of the bladder: International Consensus Panel.

Alan M Nieder1, Maurizio Brausi, Donald Lamm, Michael O'Donnell, Kyouichi Tomita, Henry Woo, Michael A S Jewett.   

Abstract

The International Consensus Panel on T1 bladder tumors markers reviewed the subject from a clinical perspective. From diagnosis to treatment decisions, what are the important issues in the management of a new patient? The assessment of prognostic factors for progression requires optimal resection and documentation. The role of immediate adjuvant intravesical chemotherapy after resection remains controversial. How often should the upper tract be assessed for tumor recurrence? The decision on whether to attempt bladder conservation with intravesical therapy or to perform a cystectomy is the most difficult issue in the management of superficial bladder cancer today. Finally, what therapies exist if initial intravesical bacille Calmette-Guérin fails to eradicate the disease or prevent recurrence? The panel thoroughly explored all these subjects and has made recommendations with supporting evidence.

Entities:  

Mesh:

Year:  2005        PMID: 16399419     DOI: 10.1016/j.urology.2005.08.066

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  34 in total

Review 1.  Treatment options for BCG failures.

Authors:  Michael A O'Donnell; Andreas Boehle
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  A rare case of synchronous bilateral epididymal and testicular metastases of urothelial carcinoma of the bladder after intravesical bacillus Calmette-Guérin.

Authors:  Naotaka Nishiyama; Yoshinori Ikehata; Noriko Okuno; Masakiyo Sasahara; Ippei Sakamaki; Yoshihiro Yamamoto; Hiroshi Kitamura
Journal:  Int Cancer Conf J       Date:  2020-09-30

3.  Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study.

Authors:  Naoto Kamiya; Hiroyoshi Suzuki; Takahito Suyama; Masayuki Kobayashi; Satoshi Fukasawa; Nobuyuki Sekita; Kazuo Mikami; Naoki Nihei; Yukio Naya; Tomohiko Ichikawa
Journal:  Int J Clin Oncol       Date:  2016-10-15       Impact factor: 3.402

Review 4.  The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside.

Authors:  Jonathan J Duplisea; Sharada Mokkapati; Devin Plote; Kimberly S Schluns; David J McConkey; Seppo Yla-Herttuala; Nigel R Parker; Colin P Dinney
Journal:  World J Urol       Date:  2018-11-11       Impact factor: 4.226

5.  Pyuria predicts poor prognosis in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin.

Authors:  Takeshi Azuma; Yasushi Nagase; Masaya Oshi
Journal:  Mol Clin Oncol       Date:  2015-06-15

Review 6.  Implementing risk-aligned bladder cancer surveillance care.

Authors:  Florian R Schroeck; Nicholas Smith; Jeremy B Shelton
Journal:  Urol Oncol       Date:  2018-02-13       Impact factor: 3.498

7.  Saudi Oncology Society clinical management guidelines for urinary bladder cancer.

Authors:  Khaled Al Othman; Shouki Bazarbashi; Khalid Balaraj; Mohamed Al Otaibi; Baher Kamal; Ibraheem Al Oraifi; Eyad Al Saeed; Khalid Al Gamdi; Ali Jubran; Ahmad Salah; Jalal Al Shareef; Jamal Zekri
Journal:  Urol Ann       Date:  2011-03

Review 8.  High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.

Authors:  Oscar Rodriguez Faba; Joan Palou; Alberto Breda; H Villavicencio
Journal:  World J Urol       Date:  2012-10-16       Impact factor: 4.226

9.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

10.  Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis.

Authors:  Behfar Ehdaie; Dan Theodorescu
Journal:  Indian J Urol       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.